| Excerpt | Reference |
|---|
| "PTSD is particularly likely to be comorbid with affective disorders, other anxiety disorders, somatization, substance abuse, and dissociative disorders." | ( Brady, KT, 1997) |
| "PTSD is a possible sequela of exposure to traumatic events." | ( Krashin, D; Oates, EW, 1999) |
| "PTSD is associated with increased regional blood flow in limbic areas and the right temporal and parietal cortex compared with age-matched normal volunteers." | ( Cohen, M; Kling, A; Lake, R; Sachinvala, N; Suffin, S, 2000) |
| "PTSD is a serious, complex and often chronic mental illness that may follow exposure to a traumatic event." | ( Rothbaum, BO; Schwartz, AC, 2002) |
| "PTSD is also often comorbid with other psychiatric disorders, especially with alcohol dependence." | ( Karlović, D; Martinac, M; Marusić, S, 2004) |
| "PTSD is considered as a multisystemic dysregulation, involving the hypothalamic- pituitary - adrenal axis, adrenergic hypersensibility, and serotonergic dysfunction." | ( Martényi, F, 2004) |
| "The observations in PTSD are part of a growing body of neuroendocrine data providing evidence of insufficient glucocorticoid signaling in stress-related neuropsychiatric disorders." | ( Yehuda, R, 2005) |
| "PTSD is a psychiatric disorder that develops in some people after exposure to trauma." | ( Dierks, MR; Jordan, JK; Sheehan, AH, 2007) |
| "PTSD is defined by the coexistence of three clusters of symptoms: re-experiencing, avoidance and hyperarousal, which persist for at least 1 month in survivors of the event (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition)." | ( Gispan, I; Kesner, Y; Merenlender, A; Shalit, F; Yadid, G; Zohar, J, 2009) |
| "The course of PTSD is often chronic and impedes individual's functioning." | ( Bravo-Mehmedbasić, A; Dzubur-Kulenović, A; Kucukalić, A, 2008) |
| "PTSD is an anxiety disorder that can occur after experiencing or witnessing a life-threatening event, such as military combat, natural disasters, terrorist attacks, serious accidents, or violent personal assaults." | ( Cates, ME; Freeman, MK; Taylor, HR, 2008) |
| "Post traumatic stress disorder is frequent in the general population (7." | ( Costa, MC; Fiks, JP; Mello, MF; Schoedl, AF, 2008) |
| "Rates of PTSD are not statistically different in combat casualties receiving midazolam during intraoperative procedures." | ( Black, IH; DeSocio, PA; Garza, TH; Gaylord, KM; Maani, CV; McGhee, LL, 2009) |
| "Chronic pain and PTSD are known to hold substantial comorbidity following traumatic injury." | ( Beck, JG; Bennett, SA; Clapp, JD; Masci, J, 2010) |
| "PTSD is a complex disorder, which frequently occurs in comorbidity with anxious disorder, personality disorder, addiction or substance abuse disorder, depressive disorder with or without psychotic symptoms and psychotic disorder." | ( Caratan, S; Mihanović, M; Presecki, P; Silić, A; Vuina, AL, 2010) |
| "PTSD is an anxiety disorder related to exposure to a severe psychological trauma." | ( Garner, B; Hetrick, SE; Parslow, R; Purcell, R, 2010) |
| "Given that PTSD is marked by deficits in anxiety/stress regulation and in social functioning, and that oxytocin is implicated in both of these areas, oxytocin seems a likely candidate for treatment of patients with PTSD." | ( Denys, D; Langeland, W; Olff, M; Witteveen, A, 2010) |
| "Although PTSD is associated with supersensitivity to glucocorticoids; prior studies have not evaluated the effect of comorbid MDD." | ( Charney, D; Gill, J; Luckenbaugh, D; Vythilingam, M, 2010) |
| "Individuals with PTSD are more likely to smoke and have greater difficulty quitting smoking." | ( Beckham, JC; Calhoun, PS; Clancy, CP; Collie, CF; Dennis, MF; Johnson, YC; Lee, S; McClernon, FJ; Vrana, SR; Wagner, HR, 2011) |
| "However, PTSD is a complex disorder and opposite neuroendocrinological changes have also been reported." | ( Elbert, T; Kirschbaum, C; Kolassa, IT; Pfeiffer, A; Stalder, T; Steudte, S, 2011) |
| "In conclusion, PTSD is associated with presence and severity of coronary atherosclerosis and predicts mortality independent of age, gender, and conventional risk factors." | ( Ahmadi, N; Budoff, M; Ebrahimi, R; Hajsadeghi, F; Mirshkarlo, HB; Yehuda, R, 2011) |
| "PTSD is a chronic and debilitating anxiety disorder characterized by exaggerated fear and/or anxiety that may develop as a result of exposure to a traumatic event." | ( Lebonville, CL; Lysle, DT; Szczytkowski-Thomson, JL, 2013) |
| "Current PTSD is characterized by reduced lymphocyte GR hormone-binding potential and by disturbed compensation between Bmax and hormone-binding affinity." | ( Damjanović, S; Dunđerski, J; Elaković, I; Jovanović, SM; Knežević, G; Matić, G; Milutinović, DV; Nestorov, J; Perišić, T; Savić, D; Špirić, Ž; Vermetten, E, 2013) |
| "Given that PTSD is frequently comorbid with substance abuse and dependence, including methamphetamine (METH), the current study sought to investigate the effects of SPS on METH-induced behavioral sensitization." | ( Eagle, AL; Perrine, SA, 2013) |
| "PTSD is associated with reduced GABA in the right anterior insula." | ( Crowley, DJ; Jensen, JE; Rauch, SL; Rosso, IM; Silveri, MM; Weiner, MR, 2014) |
| "However, PTSD is not simply a psychiatric disorder." | ( Levine, AB; Levine, LM; Levine, TB, 2014) |
| "PTSD is a debilitating neuropsychiatric disorder and many patients do not respond sufficiently to current treatments." | ( Alaluf, LG; Laukova, M; Pucillo, L; Sabban, EL; Serova, LI, 2014) |
| "PTSD is characterized by an exaggerated fear response which fails to extinguish over time and cannot be inhibited in safe contexts." | ( Frijling, JL; Koch, SB; Nawijn, L; Olff, M; van Zuiden, M; Veltman, DJ, 2014) |
| "PTSD is associated with increased risk for comorbid major depression, substance use disorder, suicide, and a variety of other mental and physical health conditions." | ( Cullen, PK; Delahanty, DL; Hruska, B, 2014) |
| "PTSD is related to adverse birth outcomes via physiological and behavioral alterations, such as smoking." | ( Lopez, WD; Seng, JS, 2014) |
| "Many veterans with PTSD are hesitant to engage in trauma-focused exposure treatments; therefore briefer, non-exposure-based treatments are needed; one such promising approach is an abbreviated Primary Care brief Mindfulness Program (PCbMP)." | ( Bergen-Cico, D; Pigeon, W; Possemato, K, 2014) |
| "Heavy drinking in PTSD is associated with partially neutralized neurotransmitter imbalance, but also with neuronal injury commonly observed in AUD." | ( Abé, C; Batki, SL; Meyerhoff, DJ; Pennington, DL, 2014) |
| "To determine if PTSD is associated with reward impairments, we conducted a systematic review of studies in which reward functioning was compared between PTSD patients and healthy control participants, or investigated in relation to PTSD symptom severity." | ( Frijling, JL; Koch, SB; Nawijn, L; Olff, M; van Zuiden, M; Veltman, DJ, 2015) |
| "PTSD is associated with significant comorbidity, especially with mood disorders and substance abuse." | ( de Bartolomeis, A; De Berardis, D; Di Giannantonio, M; Fornaro, M; Iasevoli, F; Marini, S; Martinotti, G; Mazza, M; Orsolini, L; Pompili, M; Sepede, G; Serroni, N; Tempesta, D; Tomasetti, C; Valchera, A; Vellante, F, 2015) |
| "PTSD is associated with significant morbidity and its prevention could reduce a significant burden of individual and societal suffering." | ( Argolo, FC; Cavalcanti-Ribeiro, P; Netto, LR; Quarantini, LC, 2015) |
| "The treatment of PTSD is challenging, frequently requiring specialist input from psychiatrists." | ( Eaton, S; Togno, J, 2015) |
| "In women, PTSD is positively correlated with war era child death and spousal separation." | ( Korinek, K; Loebach, P; Teerawichitchainan, B, 2017) |
| "PTSD is characterized by heightened noradrenergic signaling, as well as a resistance to extinction learning." | ( Fitzgerald, PJ; Giustino, TF; Maren, S, 2016) |
| "PTSD is considered as a memory disorder within a Pavlovian fear conditioning and extinction framework." | ( Huang, F; Li, CQ; Yang, Z, 2017) |
| "Post Traumatic Stress Disorder is an anxiety disorder with prolonged distortion of rational behavior." | ( Krishnamurthy, S; Reddy, NR, 2018) |
| "PTSD is also prevalent among veterans; those with comorbidity have worse outcomes than those without comorbidity." | ( Black, AC; DeViva, JC; Meshberg-Cohen, S; Petrakis, IL; Rosen, MI, 2019) |
| "PTSD is highly comorbid with cocaine use disorder (CUD), and cocaine users with PTSD + CUD are more resistant to treatment." | ( Hadad, NA; Hiller, H; Knackstedt, LA; Krause, EG; Namba, MD; Schwendt, M; Shallcross, J; Wu, L, 2018) |
| "PTSD is heterogeneous disorder that can be long lasting and often has delayed onset following exposure to a traumatic event." | ( Lin, X; Nwokafor, C; Reyes, BAS; Sabban, EL; Serova, LI; Van Bockstaele, EJ, 2019) |
| "PTSD is associated with significant disability, a large economic burden, and despite the range of therapies to treat PTSD, response to antidepressants is limited." | ( Bahji, A; Forsyth, A; Groll, D; Hawken, ER, 2020) |
| "Individuals with PTSD are more likely to develop alcohol and substance abuse related disorders." | ( De la Fuente-Ortega, E; Estay-Olmos, C; Gaschino, F; Gutierrez, C; Haeger, PA; Pautassi, RM; Plaza, W; Santibañez, N; Sotomayor-Zárate, R, 2020) |
| "PTSD is triggered by traumatic experience and many PTSD patients show signs of memory impairment." | ( Al-Qudah, MA; Alfaqih, MA; Alzoubi, KH; Shatnawi, AF, 2020) |
| "In addition, PTSD is associated with oxidative stress." | ( Ahmed, M; Alzoubi, KH; Khabour, OF, 2020) |
| "Given PTSD is highly comorbid with addiction disorders indicates a maladaptive interaction between fear and reward circuits." | ( Ng, KH; Sangha, S; Seibert, TA; Urbanczyk, PJ; Woon, EP, 2020) |
| "PTSD is associated with abnormalities in hypothalamic-pituitary-adrenal (HPA) axis activity." | ( Hamner, M; Kim, HM; King, A; Liberzon, I; Powell, C; Rajaram, N; Rauch, SAM; Simon, NM; Venners, M, 2020) |
| "PTSD is characterized by flashbacks, anxiety, and sleep disturbances." | ( Adkins, AM; Sanford, LD; Sweeten, BLW; Wellman, LL, 2021) |
| "PTSD is primarily treated with psychotherapy and medication, or a combination of psychotherapy and medication." | ( Guan, P; Han, S; Wen, L; Xu, D; Xu, S; Yang, Y; Zhu, C, 2020) |
| "PTSD is a common comorbidity associated with EDs, and patients with EDs and PTSD (ED-PTSD) are reported to have higher severities of illness, greater comorbidities, higher treatment dropouts, and poorer outcomes." | ( Brewerton, TD; Lafrance, A; Mithoefer, MC, 2021) |
| "PTSD is an established risk factor for suicide attempts and suicide death, but the mechanisms underlying this association remain unknown." | ( Bryan, AO; Bryan, CJ, 2021) |
| "PTSD is associated with stress-related hormones, including dysregulated glucocorticoid activity." | ( Adler, GK; Chen, Q; Jung, SJ; Koenen, KC; Kubzansky, LD; Nishimi, K; Roberts, AL; Sumner, JA; Tworoger, S, 2021) |
| "PTSD is characterized by abnormalities within the brain's salience network and reward circuitry, which are modulated by intranasal oxytocin." | ( Brady, KT; Flanagan, JC; Holtzheimer, PE; Joseph, JE; Moran-Santa-Maria, MM; Sippel, LM, 2021) |
| "PTSD is a risk factor for both ischemic and hemorrhagic stroke and is associated with recurrent strokes." | ( Alper, HE; Brackbill, RM; Maqsood, J; Nguyen, AM; Yu, S, 2021) |
| "Evidence that PTSD is characterised by specific psychobiological dysfunctions has contributed to a growing interest in the use of medication in its treatment." | ( Ipser, JC; Phillips, NJ; Stein, DJ; Williams, T, 2022) |
| "Nightmares in PTSD are also an independent risk factor for suicide." | ( Geldenhuys, C; Seedat, S; Steyn, P; van den Heuvel, LL, 2022) |
| "We discovered that PTSD is associated with significant activation of NLRP3 inflammasome in astrocytes sorted from GFAP-GFP transgenic mice, while administration of leptin markedly suppressed the activation of astrocytic NLRP3 inflammasome." | ( Chen, B; Cui, L; Feng, Y; Gong, W; Ji, M; Li, B; Li, X; Verkhratsky, A; Wang, S; Wu, X; Zhang, D, 2023) |
| "PTSD is associated with increased levels of inflammatory markers." | ( Coimbra, BM; D'Elia, ATD; Juruena, MF; Mello, AF; Mello, MF, 2022) |
| "Even if PTSD is primarily a psychiatric condition, it is also characterized by adverse somatic comorbidities." | ( Doyle, FJ; Gautam, A; Hammamieh, R; Jett, M; Marmar, CR; Mellon, SH; Misganaw, B; Muhie, S; Ressler, KJ; Wolkowitz, OM; Yang, R, 2022) |
| "PTSD is associated with all-cause morbidity and premature mortality, suggesting accelerated biological aging." | ( Duval, ER; Katrinli, S; King, AP; Liberzon, I; Rajaram, N; Rauch, SAM; Smith, AK, 2023) |
| Excerpt | Reference |
|---|
| "Because PTSD may become chronic and difficult to treat if unrecognized, early intervention is desirable." | ( Blake, DJ, 1986) |
| "Past psychotherapeutic approaches to posttraumatic stress disorders are discussed with reference to some of the special problems in treating the disorder in Vietnam combat veterans." | ( Hendin, H, 1983) |
| "Posttraumatic stress disorder (PTSD) often co-occurs with alcohol dependence, yet little is known about treatment of this comorbidity." | ( Brady, KT; Roberts, JM; Sonne, SC, 1995) |
| "A recent suggestion that PTSD may be one of a family of affective disorders is discussed in light of the treatment effects of MAOIs and clinical experience with Southeast Asian survivors of mass violence." | ( DeMartino, R; Mollica, RF; Wilk, V, 1995) |
| "Historically, many PTSD patients were treated with benzodiazepines, often in high dosages." | ( Adams, D; Batzer, W; Berigan, T; Ditzler, T; Harazin, J; Lettich, L; Viola, J, 1997) |
| "Post-traumatic stress disorder (PTSD) is frequently treated with antidepressant medications, especially the newer selective serotonergic antidepressants which have documented efficacy in PTSD." | ( Frueh, BC; Hamner, MB, 1998) |
| "Six outpatients with severe, chronic PTSD were treated with mirtazapine, up to 45 mg/day for 8 weeks." | ( Ahearn, E; Connor, KM; Davidson, JR; Weisler, RH, 1999) |
| "Maltreated subjects with PTSD excreted significantly greater concentrations of urinary DA and NE over 24 hours than OAD and control subjects and greater concentrations of 24 hour UFC than control subjects." | ( Baum, AS; Birmaher, B; Boring, AM; De Bellis, MD; Eccard, CH; Jenkins, FJ; Keshavan, MS; Ryan, ND, 1999) |
| "Overall, PTSD was associated with greatly reduced quality of life, but considerable improvement was achieved through treatment." | ( Connor, KM; Davidson, JR; Davison, RM; Malik, ML; Smith, RD; Sutherland, SM, 1999) |
| "Patients with PTSD may not respond to pharmacotherapy in the same manner, and it is unclear whether this is related to gender, trauma type, or other factors." | ( Connor, KM; Davidson, JR, 1999) |
| "Civilians with PTSD (n = 53) were treated for 12 weeks with fluoxetine (up to 60 mg/day) or placebo." | ( Connor, KM; Davidson, JR; Malik, ML; Sutherland, SM; Tupler, LA, 1999) |
| "To apply this tool to PTSD patients treated with selective serotonin re-uptake inhibitors in order to assess the impact of such treatment on the autonomic dysregulation characterizing these patients." | ( Cohen, H; Kaplan, Z; Kotler, M; Matar, M, 2000) |
| "Therapy reduced PTSD symptoms, provoked anxiety and heart rate." | ( Fernandez, M; Fischer, H; Frans, O; Fredrikson, M; Pissiota, A; von Knorring, L, 2001) |
| "The Clinician-Administered PTSD Scale (Child and Adolescent Version) was the primary measure used to assess treatment outcome." | ( Kaminer, D; Lockhat, R; Seedat, S; Stein, DJ; Zungu-Dirwayi, N, 2001) |
| "The Clinician-Administered PTSD Scale, the 21-item Hamilton Rating Scale for Depression, and the Clinical Global Impressions-Severity of Illness scale were administered every 2 weeks, and self-assessments were performed with a 100 mm visual analog mood scale." | ( Agid, O; Lerer, B; Shalev, AY, 2001) |
| "Severity of the patients' PTSD symptoms was assessed with the Clinician-Administered PTSD Scale." | ( Baker, DG; Bruce, AB; Ekhator, NN; Geracioti, TD; Hill, KK; Kasckow, JW; Keck, PE; Rounds-Kugler, B; Schmidt, D; West, SA; Yehuda, R, 2001) |
| "Overall PTSD symptoms as measured by the Clinician-Administered PTSD Scale (CAPS) showed a modest but statistically significant decrease with nefazodone treatment." | ( Fichtner, CG; Garfield, DA; Leveroni, C; Mahableshwarkar, A, 2001) |
| "Outpatients with chronic PTSD according to DSM-IV criteria and a score of 50 or more on the Clinician-Administered PTSD Scale, part 2, were randomly assigned to take placebo (N=186), 20 mg/day of paroxetine (N=183), or 40 mg/day of paroxetine (N=182) for 12 weeks." | ( Beebe, KL; Marshall, RD; Oldham, M; Zaninelli, R, 2001) |
| "Posttraumatic stress disorder (PTSD) symptoms may improve significantly with antidepressant medications, however some phenomena often remain refractory to the most commonly used treatments." | ( Brodrick, PS; Hamner, MB; Labbate, LA, 2001) |
| "32 Bosnian refugees with PTSD and symptoms of Depression presenting for treatment of the mental health consequences of surviving ethnic cleansing, participated in a case series study." | ( Boskailo, E; Durić-Bijedić, Z; Lewis, J; Pavković, I; Smajkić, A; Weine, S, 2001) |
| "Based on the kindling hypothesis of PTSD, this open-label study assesses clinical response to topiramate as a potential treatment for DSM-IV PTSD." | ( Berlant, J; van Kammen, DP, 2002) |
| "The last 17 patients completed the PTSD Checklist-Civilian Version (PCL-C) before treatment and at week 4." | ( Berlant, J; van Kammen, DP, 2002) |
| "Sertraline treatment of chronic PTSD is associated with rapid improvement in quality of life that is progressive and sustained over the course of more than 1 year of treatment." | ( Clary, CM; Endicott, J; Rapaport, MH, 2002) |
| "The neuroanatomy and neurobiology of PTSD will be discussed to illustrate the interface between: (1) the neural correlates of physical and sexual abuse and the presence of PTSD in adult women, and (2) the neurophysiologic pathway for healing through therapy aimed at empowering the trauma patient to take constructive action." | ( Sageman, S, 2002) |
| "Out of 34 victims, eight developed PTSD and two were currently diagnosed with PTSD using the Clinician-Administered PTSD Scale (CAPS)." | ( Asukai, N; Iwanami, A; Kato, N; Kato, T; Otani, T; Sasaki, T; Tochigi, M; Umekage, T, 2002) |
| "Clinician-Administered PTSD Scale (CAPS) scores did not differ between war veterans with PTSD and prisoners of war, but Montgomery-Asberg Depression Rating Scale (MADRS) scores were significantly higher in prisoners of war who developed PTSD than in war veterans with PTSD." | ( Jakovljević, M; Mück-Seler, D; Pivac, N; Sagud, M, 2002) |
| "There are several treatment options for PTSD, but some severe cases may require treatment with antipsychotic medications." | ( Bhatia, SC; Grant, K; Petty, F; Sattar, SP; Ucci, B, 2002) |
| "In both patients, the symptoms of PTSD gradually subsided to baseline within the first 4 weeks of antiretroviral treatment." | ( Labelle, C; Moreno, A; Samet, JH, 2003) |
| "Nine older men with chronic PTSD secondary to military or Holocaust trauma were prescribed the lipophilic alpha-1 adrenergic antagonist prazosin for treatment-resistant trauma-related nightmares." | ( Bonner, LT; Hoff, DJ; Peskind, ER; Raskind, MA, 2003) |
| "Patients with PTSD showed a significant improvement in PTSD symptoms with treatment." | ( Bremner, JD; Charney, DS; Southwick, SM; Vermetten, E; Vythilingam, M, 2003) |
| "Post-traumatic stress disorder (PTSD) is increasingly understood to be a medical disorder characterised by particular psychobiological dysfunctions that respond to specific treatments." | ( Beebe, K; Davidson, J; Seedat, S; Stein, DJ, 2003) |
| "Eleven patients with combat-related PTSD and 11 control subjects were evaluated with magnetic resonance spectroscopy as well as by morning salivary cortisol samples before and after administration of low-dose dexamethasone (." | ( Lenoci, M; Marmar, CR; Neylan, TC; Schuff, N; Weiner, MW; Yehuda, R, 2003) |
| "Posttraumatic stress disorder (PTSD) is a prevalent condition that has been shown to be responsive to pharmacotherapy." | ( Bayles-Dazet, W; Brady, KT; Killeen, TK; McRae, AL; Mellman, TA; Sonne, SC; Timmerman, MA, 2004) |
| "In addition, among the PTSD subjects, the peak change in DHEA in response to ACTH1-24 was negatively correlated with the total Clinician Administered PTSD Scale score, while the peak DHEA to cortisol ratio was inversely associated with negative mood symptoms measured by the Profile of Mood States scale." | ( Charney, DS; Gudmundsen, G; Lipschitz, DS; Morgan, CA; Mustone, ME; Rasmusson, AM; Shi, Q; Vasek, J; Vojvoda, D; Wolfe, J, 2004) |
| "Additional criteria to diagnose PTSD were Clinician Administered PTSD Scale (CAPS), and to diagnose MDD Montgomery-Asberg Depression Rating Scale (MADRAS)." | ( Buljan, D; Karlović, D; Marcinko, D; Martinac, M, 2004) |
| "Friedman, 2000) compare with prevailing PTSD treatment practices for veterans." | ( Chow, HC; Finney, JF; Greenbaum, MA; Moos, RH; Rosen, CS; Sheikh, JI; Yesavage, JA, 2004) |
| "In accordance, Clinician-Administered PTSD Scale ratings assessed after each month showed cortisol-related improvements for reexperiencing symptoms and, additionally, in one patient for avoidance symptoms." | ( Aerni, A; de Quervain, DJ; Hock, C; Nitsch, RM; Papassotiropoulos, A; Roozendaal, B; Schelling, G; Schnyder, U; Traber, R, 2004) |
| "Given that current pharmacotherapy for PTSD is inadequate, reduction of TT3 may be a new strategy for pharmacologic intervention that could contribute to more effective treatment of this disorder." | ( Karlović, D; Martinac, M; Marusić, S, 2004) |
| "A 38-year-old white woman with PTSD and bipolar disorder who had partially responded to carbamazepine was treated with oxcarbazepine." | ( Hanretta, AT; Malek-Ahmadi, P, 2004) |
| "Treatment of PTSD significantly improved resilience and reduced symptoms in this sample." | ( Connor, KM; Davidson, JR; Foa, EB; Hertzberg, MA; Payne, VM; Rothbaum, BO; Weisler, RH, 2005) |
| "Subjects met DSM-III-R criteria for PTSD and criteria for PTSD on the Clinician-Administered PTSD Scale, 1-month version (CAPS-1)." | ( Hennen, J; Reich, DB; Stanculescu, C; Watts, T; Winternitz, S, 2004) |
| "We found that treatment of PTSD patients for a year with the serotonin reuptake inhibitor (SSRI) paroxetine resulted in a 5% increase in hippocampal volume and a 35% improvement in verbal declarative memory function." | ( Bremner, JD; Vermetten, E, 2004) |
| "Psychotic PTSD patients, unresponsive to antidepressant treatment, improved significantly after treatment for either 3 or 6 weeks with risperidone." | ( Kozarić-Kovacić, D; Mück-Seler, D; Pivac, N; Rothbaum, BO, 2005) |
| "A total of 12 patients with PTSD and 12 age- and sex-matched healthy controls participated in a trace eyeblink test 6 h following intravenous administration of 30 mg of hydrocortisone." | ( Agarwal, R; Bonne, O; Charney, DS; Collin, C; Grillon, C; Hadd, K; Lawley, M; Vythilingam, M, 2006) |
| "Twenty-nine adult outpatients with PTSD were treated with open-label tiagabine for 12 weeks." | ( Abraham, K; Connor, KM; Davidson, JR; Weisler, RH; Zhang, W, 2006) |
| "Posttraumatic stress disorder (PTSD) is associated with low levels of circulating cortisol, and recent studies suggest that cortisol administration may reduce PTSD symptoms." | ( Belkind, D; Cohen, H; Gidron, Y; Kaplan, Z; Kozlovsky, N; Loewenthal, U; Matar, MA; Zohar, J, 2006) |
| "Subjects with PTSD had higher raw cortisol and higher normed (baseline-related) ACTH and 11-deoxycortisol values after metyrapone independent of treatment with fludrocortisone or placebo." | ( Daneshkhah, S; Kellner, M; Kiefer, F; Muhtz, C; Otte, C; Wiedemann, K; Yassouridis, A, 2006) |
| "Treatment of PTSD in association with other comorbid conditions is addressed, and the role of pharmacotherapy in treating early PTSD and acute stress disorder is examined." | ( Davidson, JR, 2006) |
| "We hypothesized that subjects with PTSD, as compared to nonpsychiatric controls, would show greater impairments in verbal declarative memory and working memory, but not attention, following exogenous glucocorticoid administration." | ( Golier, J; Grossman, R; Harvey, P; Maria, NS; McEwen, B; Yehuda, R, 2006) |
| "Outcome measures included PTSD symptoms (as measured by the Clinician Administered PTSD Scale, Impact of Events Scale, and Civilian Mississippi Scale for PTSD) and alcohol use severity (as measured by the Time Line Follow Back)." | ( Back, SE; Brady, KT; Sonne, SC; Verduin, ML, 2006) |
| "Veterans with chronic PTSD who were medication-free or receiving stable pharmacotherapy were randomly assigned to guanfacine (N=29) versus placebo (N=34)." | ( Henn-Haase, C; Hierholzer, RW; Lenoci, M; Lindley, SE; Marmar, CR; Metzler, TJ; Neylan, TC; Otte, C; Samuelson, KW; Schoenfeld, FB; Yesavage, JA, 2006) |
| "Bupropion SR in the treatment of PTSD had no significant effect in the current sample." | ( Becker, ME; Beckham, JC; Bukenya, DS; Dennis, MF; Hertzberg, MA; Moore, SD, 2007) |
| "The primary outcome measure was PTSD symptom severity assessed with the Clinician Administered PTSD Scale (CAPS)." | ( Calais, LA; Cañive, JM; Lundy, SL; Pickard, J; Toney, G; Villarreal, G, 2007) |
| "Studies of treatment of PTSD with valproate were located using a search protocol which was applied to the electronic databases CINAHL, EMBASE, MEDLINE and PSYCHINFO." | ( Adamou, M; Hale, AS; Plummer, W; Puchalska, S, 2007) |
| "These findings in occupational related PTSD are consistent with previously described effects of psychotherapy on anxiety disorders." | ( Aberg-Wistedt, A; Hällström, T; Högberg, G; Jacobsson, H; Jonsson, C; Larsson, SA; Nardo, D; Pagani, M; Salmaso, D; Soares, J; Sundin, O, 2007) |
| "Treatment effects on PTSD symptoms correlated positively with activation in the left superior temporal gyrus, and superior/middle frontal gyrus." | ( Booij, J; Carlier, IV; den Heeten, GJ; Gersons, BP; Habraken, JB; Lindauer, RJ; Olff, M; Uylings, HB; van Eck-Smit, BL; van Meijel, EP, 2008) |
| "The Clinician-Administered PTSD Scale (CAPS) conferred a diagnosis of PTSD at 5 months." | ( Peleg, T; Pitman, RK; Segman, R; Shalev, AY; Videlock, EJ; Yehuda, R, 2008) |
| "The clinician-administered PTSD scale (CAPS) conferred a diagnosis of PTSD at 5 months." | ( Peleg, T; Pitman, RK; Segman, R; Shalev, AY; Videlock, EJ; Yehuda, R, 2008) |
| "Forty male veterans with PTSD in a residential treatment program were randomized to flexible-dose topiramate or placebo augmentation." | ( Carlson, EB; Hill, K; Lindley, SE, 2007) |
| "Baseline Clinician-Administered PTSD Scale scores were 62." | ( Carlson, EB; Hill, K; Lindley, SE, 2007) |
| "Patients with chronic PTSD were randomized (1:1) to an 8-week double-blind, placebo-controlled treatment of guanfacine followed by a 2 month open label extension phase." | ( Davis, LL; Frazier, E; Newell, JM; Rasmusson, A; Southwick, SM; Ward, C, 2008) |
| "In this mixed group of PTSD patients with varied duration of symptoms, both SD and PTSD core symptoms improved significantly in response to individually tailored adjunctive treatment of the SD." | ( Chudakov, B; Cohen, H; Kaplan, Z; Matar, MA, 2008) |
| "For severe cases of PTSD propranolol may help victims who don't respond to any other therapy or therapy combination regain their authentic self-narrative and engage once more in life activities." | ( Bell, J, 2008) |
| "Twenty-two chronic PTSD outpatients were randomly assigned to participate in a 6-wk double-blind, placebo-controlled, crossover trial with 30 mg/kg x d DSR used as monotherapy or add-on pharmacotherapy." | ( Balan, L; Bloch, B; Deutsch, L; Dumin, E; Heresco-Levy, U; Kremer, I; Vass, A; Wolosker, H, 2009) |
| "The development of treatments for PTSD is challenging due to the complexity of the symptoms and psychiatric comorbidities." | ( Andreoli, SB; Barbosa Neto, J; Braga, LL; Bressan, RA; Costa, MC; Fiks, JP; Mari, JJ; Mattos, P; Mello, MF; Mendes, DD; Moriyama, TS; Valente, NL; Yeh, MS, 2009) |
| "Measures related to PTSD and depression were obtained before, during, and after treatment." | ( Foa, EB; Grubaugh, AL; Hamner, MB; Tuerk, PW, 2009) |
| "Pharmacotherapy of PTSD depends on clinical features and the presence of comorbid disorders." | ( Caratan, S; Mihanović, M; Presecki, P; Silić, A; Vuina, AL, 2010) |
| "Decrease in Clinician-Administered PTSD Scale scores from baseline was significantly greater for the group that received MDMA than for the placebo group at all three time points after baseline." | ( Doblin, R; Jerome, L; Mithoefer, AT; Mithoefer, MC; Wagner, MT, 2011) |
| "Given that PTSD is marked by deficits in anxiety/stress regulation and in social functioning, and that oxytocin is implicated in both of these areas, oxytocin seems a likely candidate for treatment of patients with PTSD." | ( Denys, D; Langeland, W; Olff, M; Witteveen, A, 2010) |
| "Patients with PTSD who were prescribed varenicline for smoking cessation between May 2006 and July 2008 were included; all patients had failed previous attempts to quit using nicotine replacement therapy, bupropion, or both." | ( Anderson, KD; Campbell, AR, 2010) |
| "The Clinician Administered PTSD Scale (CAPS) was administered at 1 and 6 months to identify PTSD." | ( Barton, CA; McFarlane, AC; Wittert, G; Yehuda, R, 2011) |
| "Seven PTSD patients had a repeat lumbar puncture 12 weeks later, after successful treatment of PTSD with paroxetine." | ( Alesci, S; Bonne, O; Charney, DS; Collins, C; Gill, JM; Kinkead, B; Luckenbaugh, DA; Manji, HK; Neumeister, A; Owens, MJ; Vythilingam, M; Yuan, P, 2011) |
| "Considerations about PTSD as a contraindication for interferon treatment are unjustified." | ( Budimir, J; Čajić, V; Dušek, D; Kurelac, I; Papić, N; Vince, A; Židovec Lepej, S, 2011) |
| "Twenty-four patients with PTSD by DSM-IV criteria and sleep disturbance were treated in a randomized, double-blind, placebo-controlled crossover study of 3 weeks of eszopiclone 3 mg at bedtime compared to placebo." | ( Brandes, M; Hoge, EA; Moshier, SJ; Pollack, MH; Simon, NM; Wechsler, RS; Worthington, JJ, 2011) |
| "Comorbid posttraumatic stress disorder (PTSD) and alcohol dependence (AD) may lead to a complicated and potentially severe treatment profile." | ( Drapkin, ML; Foa, EB; Hembree, EA; Oslin, D; Yasinski, C; Yusko, D, 2011) |
| "Posttraumatic stress disorder (PTSD) can be a chronic and disabling illness with a limited response to antidepressant treatment, particularly in the case of combat-induced PTSD." | ( Ahearn, EP; Becker, T; Cordes, T; Juergens, T; Krahn, D, 2011) |
| "The Clinician-Administered PTSD Scale (CAPS) (range, 0-136)." | ( Cramer, JA; Horney, RA; Huang, GD; Jones, KM; Krystal, JH; Rosenheck, RA; Stock, C; Vertrees, JE; Vessicchio, JC, 2011) |
| "Among patients with military-related PTSD with SRI-resistant symptoms, 6-month treatment with risperidone compared with placebo did not reduce PTSD symptoms." | ( Cramer, JA; Horney, RA; Huang, GD; Jones, KM; Krystal, JH; Rosenheck, RA; Stock, C; Vertrees, JE; Vessicchio, JC, 2011) |
| "Survivors who met PTSD symptom criteria during the clinical assessment were invited to receive treatment." | ( Adessky, R; Ankri, Y; Freedman, S; Israeli-Shalev, Y; Peleg, T; Shalev, AY, 2012) |
| "Proportion of participants with PTSD after treatment, as determined by the use of the Clinician-Administered PTSD Scale (CAPS) 5 and 9 months after the traumatic event." | ( Adessky, R; Ankri, Y; Freedman, S; Israeli-Shalev, Y; Peleg, T; Shalev, AY, 2012) |
| "Participants with partial PTSD before treatment onset did similarly well with and without treatment." | ( Adessky, R; Ankri, Y; Freedman, S; Israeli-Shalev, Y; Peleg, T; Shalev, AY, 2012) |
| "Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement." | ( Bradford, DW; Butterfield, MI; Hertzberg, MA; Kilts, JD; Marx, CE; Naylor, JC; Strauss, JL; Youssef, NA; Zinn, S, 2012) |
| "Posttraumatic stress disorder (PTSD) is a complex and debilitating anxiety disorder, and, although prolonged exposure therapy has been proven effective, many patients remain symptomatic after treatment." | ( Broekman, TG; de Kleine, RA; Hendriks, GJ; Kusters, WJ; van Minnen, A, 2012) |
| "Twenty-one PTSD subjects and 21 control subjects, who were traumatized but asymptomatic, closely matched comparison subjects evaluated with the Clinician-Administered PTSD Scale underwent a single-photon emission computed tomography scan with [(99m)TC]-TRODAT-1." | ( Andreoli, SB; Batista, IR; Bressan, RA; Calzavara, MB; Fadel, G; Felício, AC; Hoexter, MQ; Mari, JJ; Mello, MF; Pitman, RK; Reis, MA; Shih, MC, 2012) |
| "Current PTSD treatments typically only produce partial improvement." | ( Gamache, K; Nader, K; Pitman, RK, 2012) |
| "The severity of PTSD was evaluated by the Clinician-Administered PTSD Scale (CAPS)." | ( Chen, FY; Liu, W; Liu, ZC; Shu, XJ; Sun, XH; Wang, XP; Xue, L; Zhao, H; Zhu, C, 2013) |
| "Distinctive aspects of PTSD related to DFSA can be effectively treated by adapting CT to suit this population group." | ( Edwards, D; Padmanabhanunni, A, 2013) |
| "Fifty-five patients with PTSD underwent an 8-week exposure-based cognitive behavior therapy program and provided mouth swabs or saliva to extract genomic DNA to determine their BDNF Val66Met genotype (30 patients with the Val/Val BDNF allele, 25 patients with the Met-66 allele)." | ( Bryant, RA; Dobson-Stone, C; Felmingham, KL; Quirk, GJ; Schofield, PR, 2013) |
| "Pretreatment Clinician Administered PTSD Scale severity and BDNF Val66Met polymorphism predicted response to exposure therapy using hierarchical regression." | ( Bryant, RA; Dobson-Stone, C; Felmingham, KL; Quirk, GJ; Schofield, PR, 2013) |
| "To describe the successful treatment of PTSD associated nightmares in two patients with PTSD." | ( Alao, A; Razi, S; Selvarajah, J, 2012) |
| "Untreated individuals with PTSD (N=25) with non-combat trauma histories, and TC (N=12) and HC (N=23) participated in a magnetic resonance imaging scan and a resting PET scan with the CB1 receptor antagonist radiotracer [(11)C]OMAR, which measures the volume of distribution (VT) linearly related to CB1 receptor availability." | ( Bailey, CR; Carson, RE; Corsi-Travali, S; Gujarro-Anton, A; Henry, S; Huang, Y; Lin, SF; Najafzadeh, S; Neumeister, A; Normandin, MD; Pietrzak, RH; Piomelli, D; Potenza, MN; Ropchan, J; Zheng, MQ, 2013) |
| "In the presence of PTSD symptoms, children with ADHD experienced significantly improved ADHD symptom scores, suggesting that comorbidity does not attenuate an ADHD symptom response to GXR therapy." | ( Banga, A; Connor, DF; Grasso, DJ; Pearson, GS; Slivinsky, MD, 2013) |
| "Twenty-two PTSD patients' retrospective data was analyzed who presented at our clinic for outpatient psychotherapy treatment." | ( Fodor, KE; Perczel Forintos, D, 2013) |
| "The basic treatment for PTSD is not always associated to an improvement of sleep disturbances and nightmares." | ( Biondi, M; Carlone, C; Pallagrosi, M; Salviati, M; Todini, L; Valeriani, G, 2013) |
| "Posttraumatic stress disorder (PTSD) is a very debilitating disease refractory to current treatment with selective serotonin reuptake inhibitors (SSRIs) in up to 30 percent of patients, illustrating the need for new treatments of PTSD." | ( Fellous, JM; Krahl, SE; Langevin, JP; Stidd, DA; Vogelsang, K, 2013) |
| "There was also a reduction in PTSD symptoms in all 4 groups, but the main effect of prolonged exposure therapy was not statistically significant." | ( Bux, DA; Foa, EB; Imms, P; McLean, CP; O'Brien, CP; Oslin, D; Riggs, DS; Suvak, MK; Volpicelli, J; Yusko, DA, 2013) |
| "However, considering high rates of PTSD in the present veteran population, ongoing research work is important toward improving treatment efficiency by decreasing time to symptom amelioration and increasing the amount of symptom amelioration." | ( Powers, MB; Smits, JA; Tuerk, PW; Wangelin, BC, 2013) |
| "Outcome was measured with the PTSD Symptom Scale, Self-Report, which was assessed weekly during treatment." | ( Broekman, TG; de Kleine, RA; Hendriks, GJ; Smits, JA; van Minnen, A, 2014) |
| "Viewing post-traumatic stress disorder (PTSD) as a disorder of emotional learning, this study used a cognitive enhancer synergistically with virtual reality exposure (VRE) therapy for the treatment of PTSD." | ( Altemus, M; Cukor, J; Difede, J; Hoffman, H; Lee, FS; Olden, M; Wyka, K, 2014) |
| "Although many individuals with PTSD respond to exposure-based cognitive behavioral therapy (CBT), there are subgroups of individuals who are nonresponders, and many responders still have substantial residual symptoms." | ( Scheeringa, MS; Weems, CF, 2014) |
| "There was a trend toward DCS speeding PTSD symptom recovery during the exposure-based sessions, and evidence that the CBT and DCS group better maintained stability of gains on inattention ratings from posttreatment to the 3 month follow-up." | ( Scheeringa, MS; Weems, CF, 2014) |
| "Given the negative sequelae of trauma/PTSD, research has focused on identifying efficacious interventions that could be administered soon after a traumatic event to prevent or reduce the subsequent incidence of PTSD." | ( Cullen, PK; Delahanty, DL; Hruska, B, 2014) |
| "Clinician-Administered PTSD Scale (CAPS), Hamilton Anxiety Rating Scale (HAM-A), and Hamilton Depression Rating Scale (HAM-D-17) were used." | ( Borovac Štefanović, L; Delaš, I; Dodig, G; Jerončić, A; Kalinić, D; Mimica, N, 2014) |
| "Giving PTSD patients a choice of treatment appears to be cost-effective." | ( Doctor, JN; Feeny, NC; Le, QA; Zoellner, LA, 2014) |
| "Greater reduction of PTSD symptoms following treatment with ketamine was evident in both crossover and first-period analyses, and remained significant after adjusting for baseline and 24-hour depressive symptom severity." | ( Aan Het Rot, M; Charney, DS; Feder, A; Iosifescu, D; Kirkwood, K; Lapidus, KA; Morgan, JE; Murrough, JW; Parides, MK; Perez, AM; Saxena, S; Wan, LB, 2014) |
| "The findings have implications for PTSD treatment approaches." | ( Metzler, T; Meyerhoff, DJ; Mon, A; Neylan, TC, 2014) |
| "Depression and PTSD were assessed using the Beck Depression Inventory and Clinician-Administered PTSD Scale, respectively." | ( Baker, DG; Geyer, MA; Minassian, A; Nievergelt, CM; O'Connor, DT; Risbrough, VB, 2014) |
| "Ten outpatients with chronic PTSD, on stable medication, received 5 mg of Δ(9)-THC twice a day as add-on treatment." | ( Cooper-Kazaz, R; Mechoulam, R; Roitman, P; Shalev, A, 2014) |
| "Medications currently in use to treat PTSD were originally approved based on their efficacy in other disorders, such as major depression." | ( Binder, EB; Duncan, E; Dunlop, BW; Harvey, PD; Iosifescu, DV; Jovanovic, T; Kelley, ME; Kilts, CD; Kinkead, B; Kutner, M; Mathew, SJ; Mayberg, HS; Nemeroff, CB; Neylan, TC; Rothbaum, BO, 2014) |
| "Putative biological markers of PTSD which may influence treatment response are measured prior to randomization and after five weeks' exposure to the study medication, including: fear conditioning and extinction using psychophysiological measures; variants of stress-related genes and gene expression profiles; and indices of HPA axis reactivity." | ( Binder, EB; Duncan, E; Dunlop, BW; Harvey, PD; Iosifescu, DV; Jovanovic, T; Kelley, ME; Kilts, CD; Kinkead, B; Kutner, M; Mathew, SJ; Mayberg, HS; Nemeroff, CB; Neylan, TC; Rothbaum, BO, 2014) |
| "Aprepitant treatment had no effect on PTSD symptoms or subjective or physiological responses to stress or alcohol cues." | ( Diamond, CA; George, DT; Heilig, M; Hommer, DW; Kwako, LE; Momenan, R; Schwandt, ML; Shaham, Y; Sinha, R; Spagnolo, PA, 2015) |
| "Posttraumatic stress disorder (PTSD) often follows a chronic course, and the disorder is resistant to treatment with antidepressants and cognitive-behavioral therapy in a proportion of patients." | ( Green, B, 2014) |
| "Chronic PTSD was diagnosed using the Structured Clinical Interview for DSM-IV and Clinician Administered PTSD Scale." | ( Chau, A; Grunfeld, C; Inslicht, S; Madden, E; Neylan, TC; O'Donovan, A; Rao, MN; Richards, A; Ruoff, L; Talbot, L, 2014) |
| "GLT-1 expression in PTSD rats treated with CTX was significantly increased compared with PTSD group (98." | ( Chen, Q; He, Y; Ji, L; Li, L; Lin, L; Ran, Y; Wang, J; Wang, Z; Yang, M, 2014) |
| "We also examined whether PTSD treatment rationales tailored to individuals with symptoms of depression impact PTSD treatment preference/beliefs." | ( Feeny, NC; Rosoff, CB; Rytwinski, NK; Zoellner, LA, 2014) |
| "Four combat-related PTSD patients from the wars in Iraq and Afghanistan were treated with open-label tramadol hydrochloride (HCL), an atypical analgesic with opioid and non-opioid mechanisms of antinociception." | ( Geracioti, TD, 2014) |
| "Successful treatment of PTSD symptoms with SGB has been reported previously." | ( Hickey, MJ; Kane, S; Lipov, E; Lynch, JH; Mulvaney, SW; Rahman-Rawlins, T; Schroeder, M, 2014) |
| "Posttraumatic stress disorder (PTSD) is associated with abnormal functioning of the hypothalamic-pituitary-adrenal (HPA) axis; however, limited research has examined whether cortisol levels change following successful PTSD treatment." | ( Delahanty, DL; Feeny, N; Pacella, ML; Zoellner, L, 2014) |
| "Many veterans with PTSD are hesitant to engage in trauma-focused exposure treatments; therefore briefer, non-exposure-based treatments are needed; one such promising approach is an abbreviated Primary Care brief Mindfulness Program (PCbMP)." | ( Bergen-Cico, D; Pigeon, W; Possemato, K, 2014) |
| "Veterans with PTSD were identified in PC and randomly assigned to treatment as usual (TAU, n=21) or participation in brief 4-week Mindfulness Based Stress Reduction program (n=19)." | ( Bergen-Cico, D; Pigeon, W; Possemato, K, 2014) |
| "Posttraumatic stress disorder (PTSD) and alcohol dependence (AD) are frequently comorbid and the order in which they develop may affect the clinical presentation and response to treatment." | ( Foa, EB; McLean, CP; Su, YJ, 2014) |
| "Canadian male military personnel with PTSD, who despite standard treatment continued to experience trauma-related nightmares, received double-blind treatment with 0." | ( Boisvert, D; Fraser, G; Heber, A; Jetly, R, 2015) |
| "Thirty-six veterans with PTSD were randomly assigned to receive Prolonged exposure therapy (PE) or Present-Centered therapy (PCT)." | ( Abelson, J; Clifton, E; Defever, A; King, AP; Liberzon, I; Rauch, SA; Rothbaum, BO; Smith, E; Tuerk, PW, 2015) |
| "The changes in self-rated PTSD were significant for each treatment and without significant differences between treatments." | ( Popiel, A; Pragłowska, E; Teichman, Y; Zawadzki, B, 2015) |
| "In a group of 92 veterans with PTSD, we observed significantly higher Clinician-Administered PTSD Scale and PTSD Checklist scores in E2+ individuals, as well as alterations in salivary cortisol levels." | ( Bidiman, E; Johnson, LA; Marzulla, T; Raber, J; Wahbeh, H; Weber, S; Zuloaga, DG, 2015) |
| "Thirty-six adults with PTSD were randomized to 24 weeks of double-blind treatment with sertraline plus mirtazapine or sertraline plus placebo." | ( Campeas, R; Carcamo, J; Glass, A; Lewis-Fernandez, R; Neria, Y; Sanchez-Lacay, A; Schneier, FR; Vermes, D; Wall, MM, 2015) |
| "The second PTSD patient, who had suffered from lucid nightmares, was administered KB220Z to attenuate methadone withdrawal symptoms and incidentally reported dreams full of happiness and laughter." | ( Agan, G; Blum, K; Febo, M; Fratantonio, JL; Gold, MS; McLaughlin, T; Oscar-Berman, M; Simpatico, T, 2015) |
| "As TR-PTSD has a marked public health burden and significant limitations in terms of treatment interventions, a thorough assessment of current strategies is required." | ( Kluewer D'Amico, J; Makani, R; Parikh, T; Pradhan, B, 2016) |
| "Within subthreshold PTSD groups, the most commonly selected treatments were PE (61." | ( Bergman, HE; Feeny, NC; Kline, AC; Zoellner, LA, 2015) |
| "Diagnosis and severity of PTSD were assessed 3 months after the accidents using the Clinician-Administered PTSD Scale." | ( Hamazaki, K; Hamazaki, T; Hashimoto, K; Matsuoka, Y; Nishi, D; Noguchi, H, 2015) |
| "Although PTSD treatments are efficacious, they are associated with high drop-out rates in clinical trials and clinical practice." | ( Cerulli, C; Crean, H; Gallegos, AM; Heffner, KL; Pigeon, WR; Seehuus, M; Walsh, P, 2015) |
| "Posttraumatic stress disorder (PTSD) is a high-priority treatment area for the Veterans Health Administration (VHA), and dissemination patterns of innovative, efficacious therapies can inform areas for potential improvement of diffusion efforts and quality prescribing." | ( Abrams, TE; Alexander, B; Bernardy, NC; Friedman, MJ; Lund, BC, 2015) |
| "The treatment of PTSD is challenging, frequently requiring specialist input from psychiatrists." | ( Eaton, S; Togno, J, 2015) |
| "We assessed severity of PTSD (Clinician Administered PTSD Scale [CAPS]) and depression (Beck Depression Inventory-II [BDI-II]) as well as history of early life trauma (Early Trauma Inventory [ETI]) and affectivity (Positive and Negative Affect Schedule [PANAS])." | ( Abu-Amara, D; Bersani, FS; Bierer, LM; Coy, M; Epel, ES; Flory, J; Lindqvist, D; Makotine, I; Marmar, C; Mellon, SH; Reus, VI; Wolkowitz, OM; Yehuda, R, 2016) |
| "There was no effect on PTSD symptoms, no effect of psychotherapy and no interaction between psychotherapy and medicine." | ( Buhmann, CB; Carlsson, J; Ekstroem, M; Mortensen, EL; Nordentoft, M, 2016) |
| "Traumatic events and PTSD symptoms were tested for association with drug use, treatment interruption, and counseling adherence in the same month, one month later, and two months later." | ( Brooner, RK; Kidorf, MS; King, VL; Peirce, JM, 2016) |
| "Every 10% increase in PTSD symptom severity was associated with a 36% increased risk of treatment interruption two months later." | ( Brooner, RK; Kidorf, MS; King, VL; Peirce, JM, 2016) |
| "Both traumatic events and PTSD symptoms are associated with increased risk of treatment interruption, resulting in SUD patients leaving treatment at precisely the time they could benefit from treatment support." | ( Brooner, RK; Kidorf, MS; King, VL; Peirce, JM, 2016) |
| "Prazosin was not effective in treating PTSD symptoms, improving sleep, or reducing alcohol consumption overall in this dually diagnosed group." | ( Arias, A; Desai, N; Gueorguieva, R; Jane, JS; O'Brien, E; Petrakis, IL; Ralevski, E; Sevarino, K; Southwick, S, 2016) |
| "Many conceptualize PTSD as a disorder of emotion dysregulation, and clinicians often fear that emotion regulation impairments will not change with stand-alone PTSD treatments, particularly for individuals with pre-existing emotion regulation difficulties." | ( Feeny, NC; Jerud, AB; Pruitt, LD; Zoellner, LA, 2016) |
| "Under placebo, male PTSD patients showed diminished right CeM to left ventromedial prefrontal cortex (vmPFC) connectivity compared with male trauma-exposed controls, which was reinstated after OT administration." | ( Frijling, JL; Koch, SB; Nawijn, L; Olff, M; van Zuiden, M; Veltman, DJ, 2016) |
| "If these inhibitory deficits underlie PTSD, then inhibition should improve with successful treatment, with those treated with prolonged exposure (PE) potentially resulting in greater changes in inhibition than those treated with sertraline." | ( Bedard-Gilligan, M; Echiverri-Cohen, A; Feeny, N; Gallop, R; Jaeger, J; Zoellner, LA, 2016) |
| "Clinicians may improve retention in PTSD-AD treatments by monitoring symptom change at regular intervals, and eliciting patient feedback on these changes." | ( Alpert, E; Foa, EB; McLean, CP; Rosenfield, D; Zandberg, LJ, 2016) |
| "Posttraumatic stress disorder (PTSD), chronic pain, and substance use disorders are prevalent co-occurring conditions that are challenging to treat individually, and there is no evidence-based treatment for all 3." | ( Batki, SL; Bertenthal, D; Madden, E; Maguen, S; Neylan, TC; Seal, KH; Stein, MB; Striebel, J, 2016) |
| "The most widely accepted treatment for PTSD is prolonged exposure (PE) therapy, but for many patients it is intolerable or ineffective." | ( Amoroso, T; Workman, M, 2016) |
| "The Clinician-Administered PTSD Scale (CAPS) evaluated PTSD and PTSD symptoms." | ( Adessky, R; Ankri, Y; Freedman, S; Gilad, M; Israeli-Shalev, Y; Qian, M; Shalev, AY, 2016) |
| "The lingering prevalence of PTSD, despite efficient interventions, illustrates a nonremitting, treatment-refractory subset of survivors and outlines a major clinical and public health challenge." | ( Adessky, R; Ankri, Y; Freedman, S; Gilad, M; Israeli-Shalev, Y; Qian, M; Shalev, AY, 2016) |
| "For those with PTSD, a suggested treatment approach is long-term supportive psychotherapy with drug treatment directed at reducing the most disruptive symptoms, such as insomnia, nightmares, and irritability or psychosis." | ( Kinzie, JD, 2016) |
| "Combat veterans with PTSD underwent 6 weeks of VR exposure therapy combined with either d-cycloserine (DCS), alprazolam (ALP), or placebo (PBO)." | ( Bradley, B; Breazeale, KG; Davis, M; Duncan, E; Gerardi, M; Jovanovic, T; Norrholm, SD; Price, M; Ressler, KJ; Rizzo, A; Rothbaum, BO; Tuerk, PW, 2016) |
| "There is a range of therapies to treat Post Traumatic Stress Disorder (PTSD) but treatment resistance remains high, with many sufferers experiencing the chronic condition." | ( Sessa, B, 2017) |
| "Post-traumatic stress disorder (PTSD) displays high co-morbidity with major depression and treatment-resistant depression (TRD)." | ( Brand, SJ; Harvey, BH, 2017) |
| "Veterans with PTSD and SUD per DSM-IV criteria (N = 35) were randomly assigned to receive a double-blind, 8-week course of N-acetylcysteine (2,400 mg/d) or placebo plus cognitive-behavioral therapy for SUD (between March 2013 and April 2014)." | ( Back, SE; Brady, KT; DeSantis, SM; Gray, KM; Gros, DF; Hamner, MB; Kalivas, PW; Korte, KJ; Leavitt, V; Malcolm, R; McCauley, JL, 2016) |
| "We assessed PTSD symptoms and threat sensitivity using the Clinician Administered PTSD Scale in 735 Veterans Affairs patients (35% current PTSD; 16% remitted PTSD) who participated in the Mind Your Heart Study (mean age=59±11; 94% male)." | ( Ahmadian, AJ; Cohen, BE; Edmondson, D; Neylan, TC; O'Donovan, A; Pacult, MA, 2017) |
| "Assessments of coping, PTSD, and AD were conducted at pre-treatment, mid-treatment, post-treatment, 3-month follow-up, and 6-month follow-up." | ( Asnaani, A; Chazin, D; Foa, EB; Yu, J; Zandberg, LJ; Zang, Y, 2017) |
| "The Clinician-Administered PTSD Scale (CAPS) was administered at baseline (within 10 days posttrauma) and at 1." | ( Biesheuvel, TH; Frijling, JL; Goslings, JC; Honig, A; Koch, SBJ; Luitse, JS; Nawijn, L; Olff, M; van Zuiden, M; Veltman, DJ, 2017) |
| "We assessed PTSD severity using the Clinician-Administered PTSD Scale." | ( Hayes, JP; Hayes, SM; Logue, MW; McGlinchey, RE; Milberg, WP; Miller, MW; Reagan, A; Sadeh, N; Salat, D; Schichman, SA; Sperbeck, E; Spielberg, JM; Stone, A; Verfaellie, M; Wolf, EJ, 2017) |
| "Attempts to treat with standard PTSD therapies were unsuccessful." | ( Braxton, EE; Daya, SK; Lin, R; Mathis, DA; Paulus, AO; True, MW; Vroman, PJ, 2017) |
| "Integrating psychological treatment for PTSD and smoking cessation treatment enhances smoking cessation for participants with moderate or severe PTSD symptom severity, but does not enhance smoking cessation for participants with low baseline PTSD severity." | ( Asnaani, A; Foa, EB; Gariti, P; Imms, P; Rosenfield, D; Zandberg, LJ, 2017) |
| "Both PTSD- (n=37) and PTSD+ (n=25) participants showed significant startle increases in the presence of the danger signal during placebo and dexamethasone treatments (all p<0." | ( Gillespie, CF; Glover, EM; Jovanovic, T; Michopoulos, V; Norrholm, SD; Ressler, KJ; Rothbaum, BO; Schwartz, AC; Stevens, JS, 2017) |
| "The Clinician-Administered PTSD Scale (CAPS) Global Scores and NEO PI-R Personality Inventory (NEO) Openness and Neuroticism Scales served as outcome measures." | ( Doblin, R; Jerome, L; MacAulay, RK; Mithoefer, AT; Mithoefer, MC; Wagner, MT; Yazar-Klosinski, B, 2017) |
| "Posttraumatic stress disorder (PTSD) is a prevalent and highly disabling disorder, but there is currently no targeted pharmacological treatment for it." | ( Carson, RE; Davis, MT; DellaGioia, N; Duman, RS; Esterlis, I; Girgenti, MJ; Holmes, SE; Krystal, JH; Matuskey, D; Nabulsi, N; Pietrzak, RH; Southwick, S, 2017) |
| "Posttraumatic stress disorder (PTSD) is a chronic and often difficult-to-treat condition that is prevalent among military veterans." | ( Byrne, SP; Krystal, JH; Pietrzak, RH; Rosenheck, RA; Vessicchio, J, 2017) |
| "Women with the dissociative subtype of PTSD, a complex form associated with a history of childhood maltreatment, may have toxic levels of cortisol that contribute to intergenerational patterns of adverse health outcomes." | ( Ford, JD; Kane Low, LM; King, AP; Lee, H; Li, Y; Liberzon, I; Muzik, M; Rowe, H; Seng, JS; Sperlich, M; Yang, JJ, 2018) |
| "Using a rat model of childhood-induced PTSD, pre-pubertal stress (juvenile stress, JVS), we compared the therapeutic effects of fluoxetine and examined the effectiveness of 1 month of fluoxetine treatment following JVS and into adulthood compared to treatment in adulthood." | ( Ariel, L; Edut, S; Inbar, S; Richter-Levin, G, 2017) |
| "Posttraumatic stress disorder (PTSD) is a chronic, debilitating condition for which Prolonged Exposure (PE) therapy is highly efficacious." | ( Back, SE; Flanagan, JC; Moran-Santa Maria, MM; Sippel, LM; Wahlquist, A, 2018) |
| "Posttraumatic stress disorder (PTSD) is a chronic and debilitating condition for which clinicians sometimes turn to anticonvulsants as a treatment for symptoms." | ( Himelhoch, S; Miller, CWT; Moore, MB; Varma, A, 2018) |
| "Women with chronic PTSD were randomized to treatment with either GSK561679, a CRHR1 antagonist, or placebo." | ( Blommel, JG; Dunlop, BW; Harvey, PD; Hodgins, GE; Iosifescu, D; Mathew, SJ; Mayberg, HS; Neylan, TC, 2018) |
| "Posttraumatic stress disorder (PTSD) is a disabling prevalent and difficult-to-treat psychiatric disorder, which can develop after the exposure to severe traumatic events such as those occurring during wars and natural disasters." | ( Ahmed, M; Alzoubi, KH; Khabour, OF, 2018) |
| "Post-traumatic stress disorder (PTSD) is a chronic and debilitating condition that is often refractory to standard frontline antidepressant therapy." | ( Mitrev, L; Moaddell, R; Pradhan, B; Wainer, IW, 2018) |
| "Post-traumatic stress disorder (PTSD) is a learning-based anxiety disorder with significant public health challenges due to difficulties in treating the complex, multiple symptomology." | ( Burhans, LB; Schreurs, BG; Smith-Bell, CA, 2018) |
| "The Clinician Administered PTSD Scale (CAPS) and the Trauma History Questionnaire (THQ) were used to assess PTSD status and child abuse history respectively." | ( Inslicht, SS; Metzler, T; Neylan, TC; O'Donovan, A; Richards, A; Ross, JA; Young, DA, 2018) |
| "Post-traumatic stress disorder (PTSD) is prevalent in military personnel and first responders, many of whom do not respond to currently available treatments." | ( Doblin, R; Emerson, A; Feduccia, AA; Hamilton, S; Holland, J; Jerome, L; Mithoefer, AT; Mithoefer, MC; Wagner, M; Wymer, J; Yazar-Klosinski, B, 2018) |
| "Post-traumatic stress disorder (PTSD) is a common, debilitating condition with limited treatment options." | ( Asratian, A; Augier, G; Aukema, RJ; Balsevich, G; Ghafouri, B; Heilig, M; Hill, MN; Holm, L; Lee, FS; Lindé, J; Mayo, LM; Nätt, D; Spagnolo, PA; Stensson, N; Vecchiarelli, HA, 2020) |
| "Among PTSD-diagnosed veterans who received trauma treatment, 90." | ( Black, AC; DeViva, JC; Meshberg-Cohen, S; Petrakis, IL; Rosen, MI, 2019) |
| "Most PTSD-diagnosed veterans in buprenorphine treatment were not receiving trauma treatment." | ( Black, AC; DeViva, JC; Meshberg-Cohen, S; Petrakis, IL; Rosen, MI, 2019) |
| "Giving patients with PTSD their preferred treatment also confers important benefits, including enhancing adherence." | ( Feeny, NC; Mavissakalian, M; Roy-Byrne, PP; Zoellner, LA, 2019) |
| "To investigate PTSD pathophysiology, we conducted hypothalamo-pituitary-adrenal (HPA) negative feedback testing at 1, 4, 8 and 12 weeks after the SPS by administrating a dexamethasone (DEX) suppression test." | ( Asanuma, M; Nanba, T; Tanaka, KI; Yagi, T, 2018) |
| "Change in the Clinician-Administered PTSD Scale total scores one month after two sessions of MDMA served as the primary outcome." | ( Doblin, R; Emerson, A; Feduccia, AA; Giron, SG; Grigsby, J; Hamilton, S; Jerome, L; Mithoefer, MC; Ot'alora G, M; Poulter, B; Van Derveer, JW; Yazar-Klosinski, B, 2018) |
| "No difference in change in PTSD symptoms or symptom severity at 24 weeks was found between sertraline plus enhanced medication management, prolonged exposure therapy plus placebo, and prolonged exposure therapy plus sertraline." | ( Acierno, R; Allard, CB; Hoge, CW; Kim, HM; King, AP; Liberzon, I; Martis, B; Norman, SB; Phan, KL; Porter, K; Powell, C; Rauch, SAM; Rothbaum, BO; Simon, NM; Stein, MB; Tuerk, PW; Venners, MR, 2019) |
| "Pharmacotherapy advancements in PTSD treatment have been limited and the kappa opioid receptor system presents a new target that warrants further research." | ( Domingo, CB; Kosten, T; Lake, EP; Mitchell, BG; Shorter, DI; Walder, AM, 2019) |
| "Posttraumatic stress disorder (PTSD) is a debilitating disorder with limited medication treatment options." | ( Abdallah, CG; Amoroso, T; Averill, LA; Gueorguieva, R; Guthmiller, K; Keane, TM; Krystal, JH; Lautenschlager, K; Litz, BT; López-Roca, AL; Martini, B; Mintz, J; Peterson, AL; Roache, JD; Southwick, SM; Williamson, DE; Young-McCaughan, S, 2019) |
| "Patients with chronic PTSD and nicotine dependence (N = 142) received up to 12 sessions of smoking cessation counseling combined with varenicline or integrated prolonged exposure therapy and cessation counseling combined with varenicline." | ( Asnaani, A; Fitzgerald, HE; Foa, EB; Jerud, A; Kaczkurkin, AN, 2020) |
| "Studies in adult PTSD have suggested that cortisol is associated with treatment outcome." | ( Ensink, JBM; Lindauer, RJL; Lok, A; Op den Kelder, R; Wessel, AMA; Zantvoord, JB, 2019) |
| "Posttraumatic stress disorder (PTSD) is a debilitating disease with limited available treatment options and for which novel effective interventions constitute a significant unmet need." | ( Bogin, V; Dobrovolsky, A; Meloni, EG, 2019) |
| "The mild-moderate baseline level of PTSD symptom severity and short follow-up time limit the generalizability of these findings, but the study suggests that SGB merits further trials as a PTSD treatment adjunct." | ( Bartoszek, M; Constantinescu, O; Croxford, J; Hirsch, S; Kane, S; Kim, E; Lynch, JH; McLean, B; Morgan, JK; Mulvaney, S; Munoz, B; Nguyen, C; Rae Olmsted, KL; Turabi, A; Vandermaas-Peeler, R; Wallace, D; Walters, BB; White, R; Young, R, 2020) |
| "Despite the large comorbidity between PTSD and opioid use disorders, as well as the common treatment of physical injuries resulting from trauma with opioids, the ability of opioid treatments to subsequently modify PTSD-related behavior has not been well studied." | ( Evans, CJ; Fanselow, MS; Li, K; Pennington, ZT; Rajbhandari, AK; Trott, JM; Walwyn, WM, 2020) |
| "CG was associated with lower PTSD treatment response (odds ratio (OR) = 0." | ( Acierno, R; Baker, AW; Bui, E; Charney, ME; Goetter, EM; Hellberg, SN; Hoeppner, SS; Kim, HM; Lubin, RE; Malgaroli, M; Norman, SB; Rauch, SAM; Robinaugh, DJ; Simon, NM; Smith, E, 2020) |
| "Comorbid CG is associated with elevated PTSD severity and independently associated with poorer endpoint treatment outcomes in veterans with combat-related PTSD, suggesting that screening and additional intervention for CG may be needed." | ( Acierno, R; Baker, AW; Bui, E; Charney, ME; Goetter, EM; Hellberg, SN; Hoeppner, SS; Kim, HM; Lubin, RE; Malgaroli, M; Norman, SB; Rauch, SAM; Robinaugh, DJ; Simon, NM; Smith, E, 2020) |
| "PTSD-like symptoms and reactivity to PTSD-related cues were examined 3-14 days after oxytocin treatment." | ( Ammassari-Teule, M; Borreca, A; Gisquet-Verrier, P; Le Dorze, C; Pignataro, A, 2020) |
| "MDMA-assisted psychotherapy for PTSD resulted in PTG and clinical symptom reductions of large-magnitude effect sizes." | ( Belser, AB; Emerson, A; Feduccia, AA; Gorman, I; Hamilton, S; Hennigan, C; Jerome, L; Shechet, B; Yazar-Klosinski, B, 2020) |
| "These results suggest that PTSD treatment outcomes for cannabis users may be similar to nonusers when use is stopped during treatment." | ( Bremer-Landau, J; Hale, AC; McDowell, JE; Rodriguez, JL; Wright, TP, 2021) |
| "To examine long-term change in PTSD symptoms and additional benefits/harms after 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treatment of PTSD." | ( Doblin, R; Emerson, A; Feduccia, AA; Hamilton, S; Jerome, L; Mithoefer, MC; Wang, JB; Yazar-Klosinski, B, 2020) |
| "While research on ketamine for PTSD is still in its early stages, it brings about the promise of novel and more effective treatments for this disabling condition." | ( Charney, DS; Feder, A; Rutter, SB; Schiller, D, 2020) |
| "Fifty-four males with PTSD-AUD and 43 male HC received three intranasal treatment conditions (placebo, oxytocin 20 International Units (IU), and oxytocin 40 IU) in a randomized order, across three separate testing days, as part of a double-blind, crossover parent study." | ( Ahmadi, E; De Coster, L; Delucchi, K; Morrison, TE; O'Donovan, A; Stauffer, CS; Wen, J; Woolley, J, 2020) |
| "Our data suggest PTSD-AUD is associated with higher automatic imitation than HC in the absence of oxytocin administration." | ( Ahmadi, E; De Coster, L; Delucchi, K; Morrison, TE; O'Donovan, A; Stauffer, CS; Wen, J; Woolley, J, 2020) |
| "Among those without a PTSD diagnosis at posttreatment, sleeping difficulties (63." | ( Allard, CB; Kim, HM; Martis, B; Norman, SB; Rauch, SAM; Simon, NM; Stein, MB; Tripp, JC; Venners, MR, 2020) |
| "Posttraumatic stress disorder (PTSD) is often a chronic condition, despite the availability of various evidence-based treatment options." | ( Bostoen, T; Breeksema, JJ; Krediet, E; Schoevers, RA; van den Brink, W; Vermetten, E, 2020) |
| "Patients (N = 200) with chronic PTSD were randomized to "choice" (prolonged exposure [PE] or sertraline) or "no choice" (re-randomized to PE or sertraline) and received up to 10 weeks of treatment." | ( Baier, AL; Feeny, NC; Klein, AB; Kline, AC; Zoellner, LA, 2020) |
| "Equine-assisted therapy (EAT), a novel PTSD treatment, may complement existing PTSD interventions." | ( Arnon, S; Bergman, M; Fisher, PW; Hamilton, AJ; Hamilton, JF; Lazarov, A; Lowell, AL; Markowitz, JC; Neria, Y; Ryba, M; Suarez-Jimenez, B; Turner, JB; Zhu, X; Zilcha-Mano, S, 2021) |
| "Nineteen veterans with PTSD completed eight weekly group sessions of EAT undergoing multimodal MRI assessments before and after treatment." | ( Arnon, S; Bergman, M; Fisher, PW; Hamilton, AJ; Hamilton, JF; Lazarov, A; Lowell, AL; Markowitz, JC; Neria, Y; Ryba, M; Suarez-Jimenez, B; Turner, JB; Zhu, X; Zilcha-Mano, S, 2021) |
| "Post-traumatic stress disorder (PTSD) is difficult to treat but one promising strategy is to block memory reconsolidation of the traumatic event." | ( Birmes, P; Bourcier, A; Dupuch, L; El Hage, W; Jasse, L; Lamy, P; Roullet, P; Thalamas, C; Vaiva, G; Véry, E; Yrondi, A, 2021) |
| "Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective." | ( Amar, S; Amiaz, R; Bogenschutz, M; Brown, R; Carlin, S; Coker, A; de Boer, A; Doblin, R; Emerson, A; Garas, W; Gelfand, Y; Gorman, I; Hamilton, S; Hapke, E; Harrison, C; Klaire, SS; Kleiman, S; Lilienstein, A; Marta, C; Matthews, R; Mitchell, JM; Mithoefer, A; Mithoefer, M; Nicholas, C; Ot'alora G, M; Paleos, C; Parker-Guilbert, K; Poulter, B; Quevedo, S; Shannon, S; Tzarfaty, K; van der Kolk, B; Wallach, Y; Wang, JB; Wells, G; Woolley, JD; Worthy, R; Yazar-Klosinski, B, 2021) |
| "after successful PTSD psychotherapy vs." | ( Chevalier, CM; Krampert, L; Novak, B; Reich, J; Rutten, BPF; Schmidt, MV; Schmidt, U; Schreckenbach, M; Schubert, CF, 2021) |
| "Post-traumatic stress disorder (PTSD) is an incapacitating trauma-related disorder, with no reliable therapy." | ( Ahdoot, H; Bareli, T; Confortti, N; Gabay, O; Jacob, A; Lictenstein, Y; Massart, R; Sapozhnikov, D; Sokolik, CM; Szyf, M; Vaisheva, F; Warhaftig, G; Yadid, G; Zifman, N, 2021) |
| "Posttraumatic stress disorder (PTSD) and opioid use disorder (OUD) may be associated with poor outcomes in rural areas where access to mental health services and opioid agonist treatment (OAT) is limited." | ( Badger, GJ; Moxley-Kelly, N; Peck, KR; Sigmon, SC, 2021) |
| "Specifically, 67% of those with PTSD had a successful opioid use disorder treatment outcome when they were assigned to receive both ODC and buprenorphine, compared to a 36% response rate among those who received buprenorphine alone." | ( Chase, AM; Griffin, ML; Hilton, BT; McHugh, RK; Weiss, RD, 2021) |
| "The Clinician Administered PTSD Scale measured hyperarousal symptoms, including sleep disruption." | ( Eric Jensen, J; Olson, EA; Ren, B; Rosso, IM; Silveri, MM, 2022) |
| "Medications typically used to treat PTSD, such as the Food and Drug Administration-approved agent sertraline, were associated with improvement in PTSD symptoms, but the effects were small." | ( Forehand, JA; Gradus, JL; Gui, J; Huybrechts, KF; Jiang, T; Kulldorff, M; Rozema, L; Schnurr, PP; Shiner, B; Trefethen, M; Vincenti, M; Watts, BV, 2022) |
| "Compared to individuals with PTSD or AUD alone, those with co-existing PTSD and AUD exhibit greater symptom severity, poorer quality of life, and poorer treatment outcomes." | ( De La Garza, R; Kosten, TR; Lane, SD; Morice, CK; Schmitz, JM; Verrico, CD; Yammine, L; Yoon, J, 2022) |
| "Veterans and service members with PTSD (n = 158) who failed previous antidepressant treatment were randomized to 8 infusions administered twice weekly of intravenous placebo (n = 54), low dose (0." | ( Abdallah, CG; Ahn, KH; Averill, LA; Baltutis, EJ; Brundige, A; Bryant, CE; Burson, RR; D'Souza, D; Gueorguieva, R; Guthmiller, KB; Hoch, MB; Keane, TM; Krystal, JH; Lautenschlager, KA; Litz, BT; López-Roca, AL; Martini, B; McCallin, JP; Mintz, J; Murff, W; Peterson, AL; Petrakis, IL; Purohit, P; Ranganathan, M; Roache, JD; Sherif, MA; Shiroma, PR; Southwick, SM; Souza, SE; Timchenko, A; Williamson, DE; Young-McCaughan, S, 2022) |
| "Ninety individuals with severe PTSD received treatment in a double-blind, placebo-controlled pivotal trial of MDMA-AT." | ( Brewerton, TD; Doblin, R; Emerson, A; Lafrance, A; Mithoefer, M; Pamplin, C; Wang, JB; Yazar-Klosinki, B, 2022) |
| "Adult participants with severe PTSD (n = 90) were randomized to three blinded trauma-focused therapy sessions with either MDMA-AT or Placebo+Therapy." | ( Brown, RT; Coker, A; Doblin, R; Emerson, A; Klaire, SS; Mitchell, JM; Nicholas, CR; Wang, JB; Yazar-Klosinski, B, 2022) |
| "Post-traumatic stress disorder (PTSD), characterized by abnormally persistent and distressing memories, is a chronic debilitating condition in need of new treatment options." | ( Benedek, DM; Canales, JJ; Eri, R; Johnson, LR; Marathe, PA; Raut, SB; Ravindran, M; Ursano, RJ; van Eijk, L, 2022) |
| "ADP administration improves PTSD-like behaviors in mice and this effect may be mediated through an mTOR-dependent improvement in synaptic function in the hippocampus." | ( Gao, F; Ji, M; Qu, Y; Tan, B; Wang, J; Wang, X; Xie, P; Yang, S; Zhu, A; Zhu, G, 2022) |
| "Post-traumatic stress disorder (PTSD) is a debilitating mental illness with limited treatment options and a high treatment dropout rate." | ( Henner, RL; Hill, KP; Keshavan, MS, 2022) |
| "Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming." | ( Bradley, E; Khan, AJ; O'Donovan, A; Woolley, J, 2022) |
| "We discovered that PTSD is associated with significant activation of NLRP3 inflammasome in astrocytes sorted from GFAP-GFP transgenic mice, while administration of leptin markedly suppressed the activation of astrocytic NLRP3 inflammasome." | ( Chen, B; Cui, L; Feng, Y; Gong, W; Ji, M; Li, B; Li, X; Verkhratsky, A; Wang, S; Wu, X; Zhang, D, 2023) |
| "Fifty-two male PTSD outpatients on stable combination treatment with SSRI and benzodiazepines, with persistent sleep disturbances not responding to prescription of zolpidem, flurazepam, nitrazepam, promazine, and levopromazine, were assessed for sleep disturbances improvements after prescription of quetiapine in the evening." | ( Karlović, D; Ljubičić Bistrović, I; Ljubičić, R; Matošić, A; Peitl, V; Vilibić, M; Vlatković, S; Živković, M, 2022) |
| "As a result, effective management of PTSD requires mindfulness of the timing of drug administration." | ( Abbasian, K; Chamanara, M; Hemmati, S; Hosseini, Y; Nassireslami, E; Sadeghi, MA; Yousefi Zoshk, M, 2022) |
| "People with BD and PTSD may experience different outcomes and quality of life after pharmacologic treatment than those with BD alone." | ( Ashton, MM; Berk, M; Dean, OM; Kavanagh, BE; Russell, SE; Skvarc, D; Turner, A; Wrobel, AL, 2023) |
| "Comorbid PTSD may affect quetiapine and lithium treatment response in those with BD." | ( Ashton, MM; Berk, M; Dean, OM; Kavanagh, BE; Russell, SE; Skvarc, D; Turner, A; Wrobel, AL, 2023) |
| "The primary outcome is PTSD symptom severity as indexed by the PTSD Checklist for DSM-5 (PCL-5) assessed at post treatment (Week 9) and follow-up (Week 13)." | ( Fischer, CM; Papini, S; Rubin, M; Telch, MJ; Zaizar, ED, 2022) |
| "Post-traumatic stress disorder (PTSD) is often treated by (1) selective serotonin reuptake inhibitors (SSRIs), (2) exposure therapy, or a combination of the two." | ( Ohmura, Y, 2023) |
| "BDNF-HA2TAT/AAV therapeutically effects PTSD caused by SPS, with changes seen in plasma corticosterone and BDNF-TrkB pathways within the hippocampus; therefore, BDNF-HA2TAT/AAV may be a promising treatment for patients with PTSD." | ( Dang, Y; Deng, L; Ma, C; Zhang, H; Zhang, L, 2023) |
| "Female adult Wistar rats subjected to PTSD were treated with moderate treadmill exercise or fluoxetine, or a combination of both." | ( Akhoundzadeh, K; Nikkhah, F; Shafia, S, 2023) |
| "Thirty participants with co-occurring PTSD and OUD were randomized to receive either: (a) continued medications for OUD (MOUD) treatment as usual (TAU), (b) Prolonged Exposure therapy (PE), or (c) PE with financial incentives delivered contingent upon PE session attendance (PE+)." | ( Badger, GJ; Cole, R; Higgins, ST; Moxley-Kelly, N; Peck, KR; Sigmon, SC, 2023) |
| "In adults with anxiety disorders and PTSD, evidence supports a relatively safe profile for medical cannabis; however, conclusive scientific evidential support of its therapeutic properties is limited, resulting in a lack of standardization and Food and Drug Administration approval." | ( Haycraft, AL, 2023) |
| "The primary outcome measure for PTSD will be the Clinician Administered PTSD Scale-5." | ( Armstrong, SB; Davis, AK; Lancelotta, RL; Levin, AW; Nagib, PB, 2023) |
| "Fourteen LGBTQ patients with PTSD, assessed with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), received 24 sessions of twice-weekly (12 weeks) TFPP via teletherapy provided by supervised early-career therapists inexperienced in the modality." | ( Keefe, JR; Louka, C; Milrod, BL; Moreno, A; Spellun, J; Zonana, J, 2023) |
| "CAPS-5-measured PTSD symptoms, including dissociation, significantly improved during treatment (mean decrease=-21." | ( Keefe, JR; Louka, C; Milrod, BL; Moreno, A; Spellun, J; Zonana, J, 2023) |
| "TFPP shows promise in the treatment of PTSD among sexual and gender minority patients seeking LGBTQ-affirmative PTSD care." | ( Keefe, JR; Louka, C; Milrod, BL; Moreno, A; Spellun, J; Zonana, J, 2023) |
| "We found that PTSD was associated with significant activation of the NLRP3 inflammasome in DRN, whereas administration of SA significantly inhibited DRN NLRP3 inflammasome activation and reduced DRN apoptosis level." | ( Kong, F; Ma, L; Mei, T, 2023) |
| "A total of 120 eligible patients with PTSD will be recruited and randomised into EFT, written exposure therapy (WET) or WL groups." | ( Cho, SH; Choi, S; Choi, Y; Choi, YE; Kim, H; Kim, Y; Kwon, DH; Kwon, O; Lee, SH, 2023) |
| "Post-traumatic stress disorder (PTSD) is a complex, chronic psychiatric disorder typically triggered by life-threatening events and, as yet, lacks a specialized pharmacological treatment." | ( Hu, X; Li, C; Li, Z; Lian, B; Liu, L; Lu, G; Sun, L; Sun, Y; Wang, L; Wang, Z; Yue, K; Zhou, G, 2023) |
| "We first showed that both PTSD and depressive symptoms significantly decreased over the course of esketamine treatment." | ( Bismark, A; Colvonen, P; Hunt, C; Lee, E; Nokes, B; Park, J; Ramanathan, D; Titone, MK, 2023) |
| "Veterans with PTSD and depression tend to benefit from esketamine treatment, but OSA may interfere with esketamine effectiveness." | ( Bismark, A; Colvonen, P; Hunt, C; Lee, E; Nokes, B; Park, J; Ramanathan, D; Titone, MK, 2023) |
| "Changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity score (primary endpoint) and Sheehan Disability Scale (SDS) functional impairment score (key secondary endpoint) were assessed by blinded independent assessors." | ( Balliett, B; Bogenschutz, M; de Boer, A; Doblin, R; Gelfand, Y; Hamilton, S; Harrison, C; Kleiman, S; Mitchell, JM; Mithoefer, M; Nicholas, CR; Ot'alora G, M; Paleos, C; Parker-Guilbert, K; Quevedo, S; Shannon, S; Tzarfaty, K; van der Kolk, B; Yazar-Klosinski, B, 2023) |